【摘要】 目的评价依达拉奉、巴曲酶和阿司匹林联合治疗急性脑梗死的疗效及安全性。方法对2004年4月￣2006年1月广东省普宁华侨医院80例急性脑梗死住院患者,随机分为治疗组和对照组各40例。治疗组应用依达拉奉、巴曲酶和阿司匹林联合治疗;对照组应用巴曲酶和阿司匹林治疗;评价两组治疗前及治疗后3d、7d、14d、28d、90d的神经功能缺损评分和90d后疗效。结果治疗组基本痊愈率及有效率高于对照组(P<0.05),且起效快,不增加不良反应。结论依达拉奉、巴曲酶和阿司匹林联合治疗急性脑梗死比巴曲酶和阿司匹林治疗效果更好,且较安全。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of the combined treatment of edaravone, batroxobin and aspirin on acute cerebral infarction. Methods The cases of acute cerebral infarction treated in our department from April, 2004 to January, 2006 were divided randomly into treatment group (n=40) and control group (n=40). The former was treated with edaravone, batroxobin and aspirin, while the latter was treated with batroxobin and aspirin. The scores of neurologic impairment were recorded before the treatment and 3, 7, 14, 28, 90 d after the treatment. The curative effects were evaluated at the 90th day. Results The treatment group had a significantly higher excellent rate and healing rate, lower side-effect rate as compared with the control group (P<0.05). Conclusion The combined therapy of acute cerebral infarction with edaravone, batroxobin and aspirin is more effective and safer than that with batroxobin and aspirin only.更多还原